Published Date: 02 Mar 2023
A study published online Feb. 27 in JAMA Internal Medicine found that interventions increase prevention but not the association with alcohol use disorder (AUD) in primary care.
Read Full NewsMRI offers the possibility of personalized neoadjuvant chemotherapy for patients with HER2-positive breast cancer, but it may not be ready for prime time.
Patients with non-squamous non-small cell cancer may achieve similar outcomes with a subcutaneous formulation of the immunotherapy toripalimab as with IV administration.
Conditional approval of intravesical gene therapy was supported by clinical evidence showing a 53.4% complete response rate in patients with treatment-resistant non-muscle-invasive bladder cancer.
A phase 2 study evaluates the safety and efficacy of brexucabtagene autoleucel in BTKi-naïve patients with relapsed/refractory mantle cell lymphoma.
1.
Report: High risk of lung cancer from respirable crystalline silica even below the current occupational exposure limit
2.
Studies point to redlining as a 'perfect storm' for breast cancer
3.
The pathology of incurable cancers can be predicted thanks to research.
4.
Admissions, medical schools, costs, and eligibility requirements information for FNB Head and Neck Oncology.
5.
Train Eyes so Myopia Doesn't Get Worse? Nurse Intervention for BP Post-Stroke
1.
Future of Oncology: Targeted Therapies & Collaborative Innovation Shaping Cancer Care in the USA
2.
The Future of Hemophilia Treatment: Long-Acting Therapies and Gene Editing
3.
The Dark Side of Melanoma: Uncovering the Risk Factors and Prevention Strategies
4.
Understanding the Rare Disease: Werner Syndrome Explained
5.
Colorectal Cancer Incidence Trends: A Growing Concern in 2024 and 2025
1.
International Lung Cancer Congress®
2.
Genito-Urinary Oncology Summit 2026
3.
Future NRG Oncology Meeting
4.
ISMB 2026 (Intelligent Systems for Molecular Biology)
5.
Annual International Congress on the Future of Breast Cancer East
1.
Efficient Management of First line ALK-rearranged NSCLC - Part V
2.
First-Line Maintenance Therapy for Metastatic Urothelial Carcinoma: Bridging Clinical Practice and Trials
3.
Navigating the Complexities of Ph Negative ALL - Part IV
4.
Understanding Early Relapse in B-cell ALL: Rates, Risks, and Common Sites
5.
Breaking Ground: ALK-Positive Lung Cancer Front-Line Management - Part IV
© Copyright 2026 Hidoc Dr. Inc.
Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation